Videos

"I think what we definitively have is a device that's been around for over 50 years now that now we know significantly improves quality of life," says Andrew C. Peterson, MD, MPH.

Tim A. Richardson, MD, outlines the 2 key scenarios for utilizing genetic testing in clinical practice.

"It's often a balancing act of truly kind of pinning down people on what exactly they want to treat," says Landon Trost, MD.

“The 1 main assumption that we've been very wrong on although we've had the data for a long period of time, [is that] although we assume that the stone fragments are small enough to pass, oftentimes they don't,” says Thomas Mueller, MD.

"[Veterans] may be missing out on potentially life-saving treatments, and their family might also be missing out on some benefits as well," says Daniel Kwon, MD.

“It's really a reapplication of the existing technology for BPH that is familiar to many of us already and we use in our clinical practices,” says Arvin K. George, MD.

“Opportunity wise, I always say that if you don't perform the test, then you're limiting treatment options for your patients,” says Kara Cossis, PA-C, MPH.

“When a patient knows that there are so many tools that are there for people, it gives them hope. It gives their caregivers hope,” says Joy Maulik, CRNP.

"It's a little tedious to find these patients, but it's really critical. Otherwise, you're not going to get reimbursed for these therapies," says Jason Hafron, MD.

“We then talked a little bit about BCG unresponsive disease, which is a really hot topic,” says Gautam Jayram, MD.

“We're really excited as robotic surgeons, because this will be the first time in a couple decades that there'll be competition for robots, and that's only going to make things better,” says Ronney Abaza, MD, FACS.

“The guidelines have changed. They used to be called third-line therapies, and they're no longer quote "third-line" anymore, based on the new guidelines that have come out,” says Kari Bailey, MD.

Panelists discuss how management options for nonmetastatic castration-sensitive prostate cancer (nmCSPC) include active surveillance, radiotherapy, and systemic therapy, with recommendations influenced by factors such as tumor volume, prostate-specific antigen (PSA) doubling time, and patient life expectancy, particularly for those with high-volume symptomatic disease.

“Part of the reason that we created this Working Group Session is to essentially highlight the role that APPs can play in building men's health practices,” says Andrew Y. Sun, MD.

“I would say, about 10 years ago, there was a real skepticism, a healthy skepticism, I would say, in the beginning. Now that has slowly changed into optimism,” says Arvin K. George, MD.

“I think that it is upon us as urologists to try to start to embrace this clinical accomplishment, and that being trying to make our patients as stone free as possible,” says Tom Mueller, MD.

"We only have so much time with our patients, but we want to show them that we support them," says Ava Saidian, MD.

"I cannot wait to see what the SMSNA is going to have in store next year," says Helen L. Bernie, DO, MPH.

“Certainly, I think when you have these inherent challenges or biases in the reimbursement aspects, it has to beg the question, does this or how will this impact the future of acquisition or passing down of these newer technologies?” says Kevin C. Zorn, MD, FRCSC, FACS.

"We found that almost half of them had suspicious findings as defined by the radiologist, but also that the positivity rate for PSAs below 0.5 were around 35%," says Eric Li, MD.

"I would basically look at these 3 things as the major things to be coming up," says Jitesh Dhingra, MD, FRCEM.

“On a lesion level, there were still more lesions detected with PSMA-PET, but not on a patient level,” says Jeremie Calais, MD, PhD.

Oliver Sartor, MD, discusses how unmet needs and clinical challenges for PSMA imaging in prostate cancer patients include standardizing interpretation criteria, addressing false negatives in certain tumor phenotypes, improving accessibility and cost-effectiveness, and developing strategies for patients with low PSMA expression or PSMA-negative disease.

"We were trying to understand how veterans were making decisions about germline testing for their prostate cancer," says Daniel Kwon, MD.

“I think this is the future, and if we don't go down that path and we don't explore, we're not going to make it better for us and for the patients,” says Geoffrey N. Sklar, MD, FACS.

"We were really surprised that we found that the anxiety components in the depression questions in those 3 questionnaires really improved drastically when we compared them to pretreatment vs post treatment," says Andrew C. Peterson, MD, MPH.

"For urologists that are interested in implementing Aquablation into their armamentarium, I am very envious, because anyone who is going to start doing Aquablation now is going to be using the HYDROS System," says Ravi Munver, MD.

"This is quite reassuring to show that there's no statistically significant influence of BMI in actual complications," says Muhammed A. Moukhtar Hammad, MBBCh.

“For us, being able to know where the cancer is allows us to target it, and I think that lets us be much more effective with our treatment,” says Bridget F. Koontz, MD, FASTRO.

Panelists discuss how some of the most critical challenges and unmet needs in the treatment and management of metastatic castration-sensitive prostate cancer (mCSPC) include the effectiveness of monotherapy, the need for better risk stratification, and the integration of novel therapies to improve patient outcomes.